Please login to the form below

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

Bayer, Orion prep challenge in prostate cancer market

Darolutamide is facing some entrenched, heavyweight rivals in the market for anti-androgen prostate cancer therapies, which is currently led by Johnson &Johnson with Zytiga (abiraterone acetate) and next-generation drug

Latest news

J&J’s Erleada cleared for early prostate cancer in Europe

Xtandi is also approved for more advanced, metastasised CRPC, where it competes with J&J’s $4bn-plus androgen synthesis inhibitor Zytiga (abiraterone acetate), and reported $180m in alliance revenues in
Generic threat looms to J&J’s blockbuster Zytiga in US

8, 822, 438) for Zytiga (abiraterone acetate) is invalid, and sought a preliminary injunction while that case is considered by the Court of Appeals for the Federal Circuit, which is expected
Daily Brief: NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

families. “We firmly believe that the clinical effectiveness demonstrated in the multinational, Phase 3 LATITUDE study, means that abiraterone plus ADT should be made available routinely to NHS patients that need
EMA starts review of Xtandi in non-metastatic prostate cancer

At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.
J&J’s Erleada first US drug for non-metastatic prostate cancer

momentum before Zytiga (abiraterone acetate) - its current blockbuster medicine for CRPC - faces generic competition in the US, which accounted for around half of the drug’s $2.5bn in sales in

More from news
Approximately 5 fully matching, plus 52 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

outperforming J&J's Zytiga [abiraterone].
Taking a strategic approach

But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
Pharma deals during October 2013

AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
Interview: Cesar Rodriguez, Janssen

Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Account Director, Medical Education: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

PR Associate Director – Consumer Health & Beauty: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Senior Medical Writer: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Senior Medical Writer: Competitive salary and benefits

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Director – Healthcare PR: Salary TBC

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Subscribe to our email news alerts

PMHub

Add my company

GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...